↓ Skip to main content

Phase I Study of High-Dose l-Methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH Wild-Type High-Grade Glioma

Overview of attention for article published in Cancer Research Communications, January 2022
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
10 news outlets
blogs
4 blogs
twitter
29 tweeters

Readers on

mendeley
5 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase I Study of High-Dose l-Methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH Wild-Type High-Grade Glioma
Published in
Cancer Research Communications, January 2022
DOI 10.1158/2767-9764.crc-21-0088
Pubmed ID
Authors

Lucas A. Salas, Thomas G. Stewart, Bret C. Mobley, Chengwei Peng, Jing Liu, Sudan N. Loganathan, Jialiang Wang, Yanjun Ma, Mitchel S. Berger, Devin Absher, Yang Hu, Paul L. Moots, Brock C. Christensen, Stephen W. Clark

Twitter Demographics

The data shown below were collected from the profiles of 29 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 20%
Unknown 4 80%

Demographic breakdown

Readers by professional status Count As %
Other 2 40%
Researcher 1 20%
Student > Master 1 20%
Unknown 1 20%
Readers by discipline Count As %
Medicine and Dentistry 2 40%
Immunology and Microbiology 1 20%
Biochemistry, Genetics and Molecular Biology 1 20%
Unknown 1 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 116. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 July 2022.
All research outputs
#276,893
of 21,708,871 outputs
Outputs from Cancer Research Communications
#1
of 86 outputs
Outputs of similar age
#9,547
of 475,110 outputs
Outputs of similar age from Cancer Research Communications
#1
of 17 outputs
Altmetric has tracked 21,708,871 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 86 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 475,110 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.